Mass spectrometry (MS)-based proteomics allows the comprehensive identification and quantification of proteins in various biological specimen such as cell lines, body fluids or tissues. The study of these complex samples for applications like biomarker discovery requires large sample cohorts with low technical variability to overcome inter-individual differences and achieve sufficient statistical power.

Rapid developments in the field of proteomics within recent years have enabled the reproducible and reliable quantification of large sample cohorts. Large scale studies comprising hundreds of samples are primarily processed and analyzed in one centralized facility.

Presenter: Amaury Lachaud

Date: Monday, Sep 18, 2023, 11:45 AM – 1:00 PM
Session: PP01

Advances in mass spectrometry proteomics now make it possible to achieve unprecedented depth and coverage faster than ever before. In this case study we demonstrate the advantages of our new workflow based on the Bruker timsTOF® platform, delivering unbiased high-throughput analysis of lung cancer and healthy tissue samples in less than 24 hours.

Poster 3110/17 presented at AACR 2022

Presenter: Yuehan Feng
Session: PO.TB01.04 – Patient-Derived Xenografts
Date: April 12

The primary goal of many DIA based experiments is to discover proteins or peptides (candidates) that are differentially expressed in two or more conditions. Improvements in DIA workflow are typically measured based on identification, precision, and accuracy.

Presenter: Roland Bruderer

Date: Monday, June 5
Topic area: Biomarkers: Quantitative Analysis I

New: Spectronaut^® 19

Unlock Your Data's True Story

New: Spectronaut^® 19

Unlock Your Data's True Story

Learn More